In this articleNVOFollow your favorite stocksCREATE FREE ACCOUNTNovo Nordisk and Eli Lilly took their GLP-1 pill battle to the preeminent obesity meeting this weekend as they prepare for the next sea change in how patients receive their drugs.Novo Nordisk on Sunday announced that prescriptions of the Wegovy pill have topped 3 million since it entered the U.S. market about five months ago. The Danish drugmaker’s CEO Mike Doustdar celebrated the milestone, saying in an interview with CNBC that Novo was able to accelerate prescriptions even as Lilly introduced its own GLP-1 pill in April.”If that’s not acceleration, then I don’t know what is,” Doustdar told CNBC this weekend at the American Diabetes Association’s Scientific Sessions. Meanwhile, Lilly CEO Dave Ricks told CNBC that prescriptions of its pill Foundayo are “markedly higher” than the 20,000 that Lilly reported about six weeks ago around its first-quarter earnings release, without giving a specific number. He said the number builds week over week and that Lilly is pleased with the progress. The competition for the weight loss pill market is only the latest for the longtime rivals. Signs of that tension were evident throughout the industry event this weekend. Cars drove around advertising Novo’s Wegovy pill, while pictures of Lilly’s Foundayo pill covered some of the floors of the convention center in New Orleans. And the two companies will soon make their case for their daily pills and their weekly shots to seniors. Starting in July, millions of people with Medicare will be able to access GLP-1 drugs for weight loss for $50 a month. Until now, Medicare beneficiaries have had to pay out of pocket for the obesity drugs, costing them potentially hundreds of dollars a month. Both companies say they’re focused on raising awareness of the program, though they have different pitches. Weight loss pills available: A heap of GLP-1 pillsAprott | Istock | Getty ImagesDoustdar thinks the program could be an opportunity to regain some of the ground Novo’s Wegovy shot has lost to Lilly’s Zepbound. The drugmaker plans to advertise Wegovy’s other health benefits on its label, he said, like the fact that it can decrease the risk of cardiovascular problems like heart attacks and strokes. He said Novo should win with seniors “if common sense is to prevail, and I put myself in their shoes.” “With the Wegovy high dose, why would you not take a product that has the same efficacy, percentage wise, than my competitor?” he said. “On top of it, you get kidney, liver, heart, stroke protection, let’s say free of charge. I would take it if I was 10 years older.”Lilly’s pitch to seniors is convenience. The company’s pill Foundayo can be taken at any time of day with food, water and other medicines, whereas Novo’s pill needs to be taken on an empty stomach with little water and requires fasting for 30 minutes afterward. “The main thing is, it’s easy,” Ricks said. “This is something that can just go in your daily routine. Most seniors are on many other medications, and they’ve got their pill case, and they use that every day, and this will just fit right into that without any extra thought.”Ricks said Lilly is working closely with the government to prepare, and he’s confident that Humana, which will process prescription requests, will do a good job. He thinks the program will be popular with seniors and that longer term, the initiative could help prove that obesity care should be “regular health care.” “We have to prove that in this pilot and prove cost effectiveness and then kind of reset what we expect from our health insurance, which is obesity care should be health care,” Ri …
